Article Abstract

Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib

Authors: Fernando Franco, Mariano Provencio


We have carefully read the article by Dr. Cascone et al. in which they report the results of a phase 2 study evaluating the role of the induction therapy with cisplatin plus docetaxel, followed by a surgery and erlotinib in patients with resectable non-small cell lung cancer (NSCLC). This study has been registered as NCT00254384 and the data presented in the aforementioned article correspond to long-term efficacy results (1).